GeoVax Labs, Inc. GOVX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
GeoVax Labs, Inc. (GOVX) is a healthcare company listed in the US with a market value of about $928292. In fiscal year 2025 it had revenue of $2M and net income of -$21M, a net margin of -862.3%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 0.0, 5-year revenue growth of 6% a year, a 5-year average ROIC of -301%.
About GeoVax Labs
GeoVax Labs is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $828918 in 2016 to $2M in 2025, growth of about 13.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count fell by 15% over three years (buybacks). It spends 728% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- 3-year revenue growth above 10% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $4M | $0 | $81526 | $385501 | $2M | $1M | $963203 | $1M | $828918 |
| Net income | -$21M | -$25M | -$26M | -$14M | -$19M | -$3M | -$2M | -$3M | -$2M | -$3M |
| Free cash flow | -$22M | -$25M | -$25M | -$19M | -$11M | -$3M | -$1M | — | -$2M | — |
| EPS (diluted) | $-22.40 | $-120.46 | $-14.29 | $-12.39 | $-3.04 | $-2.14 | $-781.87 | $-310981.25 | $-596131.89 | $-1589685.05 |
| Net margin | -862.3% | -632.0% | — | -17198.3% | -4817.2% | -162.2% | -201.6% | -265.8% | -201.8% | -394.7% |
| ROIC | -366.2% | -393.5% | -366.6% | -41.7% | -339.5% | -22.8% | — | — | — | -1075.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $240.00, 13976% above the current price; targets range from $240.00 to $240.00; the consensus rating is “none”; expected EPS is $-123.36 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is GeoVax Labs’s P/E ratio?
About 0.0, based on the last twelve months of diluted earnings per share.
Does GeoVax Labs pay a dividend?
Not currently.
Is GeoVax Labs a good stock to buy?
We do not give buy or sell advice. GeoVax Labs scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.